The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

BACKGROUND: The VeriStrat test is a serum proteomic signature originally discovered in non-responders to second line gefitinib treatment and subsequently used to predict differential benefit from erlotinib versus chemotherapy in previously treated advanced non-small cell lung cancer (NSCLC). Multipl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Fidler, Mary Jo, Fhied, Cristina L., Roder, Joanna, Basu, Sanjib, Sayidine, Selina, Fughhi, Ibtihaj, Pool, Mark, Batus, Marta, Bonomi, Philip, Borgia, Jeffrey A.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5861613/
https://ncbi.nlm.nih.gov/pubmed/29558888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4193-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados